UPDATE: UBS Upgrades Abbvie (ABBV) to Buy
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/4/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
- AppLovin shares fall after court denies request against Unity
Abbvie, Inc. (ABBV) Tops Q2 EPS by 6c; Guides Q3 EPS to Strong Side
July 25, 2014 7:47 AM EDT(Updated - July 25, 2014 7:50 AM EDT)
Abbvie, Inc. (NYSE: ABBV) reported Q2 EPS of $0.82, $0.06 better than the analyst estimate of $0.76. Revenue for the quarter came in at $4.93 billion versus the consensus estimate of $4.7 billion.
"This was another very strong quarter for AbbVie, as we delivered sales and earnings per share above our original guidance and announced plans to merge with Shire, a strategic action that will further enhance our long-term growth prospects," said Richard A. Gonzalez, chairman and chief executive officer, AbbVie. "Last month, we raised our 2014 earnings-per-share guidance, reflecting... More
